Early Life and Education
Panna Sharma’s career in biotechnology is rooted in an early interest in science and technology. He earned a Bachelor of Science from Boston University in the University Professors Program, where he focused on philosophy of science, neural networks, and artificial intelligence. This multidisciplinary education gave him the ability to bridge complex technical concepts with practical problem-solving in business and healthcare.
Career in Genomics and Diagnostics
Before leading Lantern Pharma, Panna sharma established himself in the world of cancer diagnostics and genomics. He served as President and CEO of Cancer Genetics, Inc., where he guided the company through international expansion and developed partnerships with pharmaceutical and biotech firms.
At Cancer Genetics, Sharma helped advance genomic technologies into clinical research, a role that shaped his belief in combining data-driven insights with targeted oncology programs. This experience became the foundation for his leadership approach at Lantern Pharma.
Taking the Helm at Lantern Pharma
In July 2018, Sharma was appointed President, CEO, and Board Member of Lantern Pharma. The company focuses on precision oncology and drug development powered by artificial intelligence. His mission was clear, make cancer drug development more efficient and cost-effective by harnessing data science and computational tools.
Instead of following the traditional path of large, expensive clinical trials, Sharma emphasized targeted, biomarker-driven studies. By narrowing trial populations, Lantern aims to demonstrate efficacy with greater speed and efficiency.
The RADR Platform Advantage
At the core of Lantern Pharma’s strategy is its proprietary RADR platform short for Response Algorithm for Drug Repositioning & Rescue. This machine-learning system analyzes vast amounts of genomic and clinical data to identify patient subgroups, predict drug responses, and prioritize drug candidates.
Panna Sharma has positioned RADR as the company’s technological edge, enabling smarter and leaner trials. By pairing computational intelligence with oncology, Lantern increases the chances of success while reducing costs and development timelines.
Clinical Milestones and Pipeline Progress
Under Sharma’s leadership, Lantern Pharma has advanced several promising drug candidates:
- LP-184: An anticancer agent being studied for tumors with specific DNA repair deficiencies.
- LP-300: In development for never-smoker non-small cell lung cancer, a subgroup often underserved in treatment research.
- LP-284: Showing preclinical and early-stage promise for lymphomas and other cancers.
Lantern has also formed Starlight Therapeutics, a subsidiary dedicated to central nervous system cancers. Recently, Starlight received FDA clearance for an Investigational New Drug (IND) application, marking an important milestone for the company’s pipeline.
These achievements demonstrate Sharma’s strategy of advancing targeted therapies while keeping clinical programs efficient and focused.
Pragmatic and Adaptive Leadership
Panna Sharma is known for his adaptability and pragmatic leadership. Rather than committing to rigid long-term trial designs, he adapts development strategies based on new clinical and biomarker data.
By leveraging partnerships with research institutions and maintaining a flexible corporate structure, Sharma ensures Lantern can pivot quickly when scientific opportunities arise. This agility helps the company operate more effectively in the resource-intensive world of oncology drug development.
Communication and Investor Confidence
As the CEO of a publicly traded company, Sharma must also maintain credibility with investors. He is recognized for clear, consistent communication highlighting RADR’s growth, regulatory milestones, and clinical updates in a way that builds trust.
His emphasis on transparency and discipline has helped reassure both stakeholders and the medical community that Lantern Pharma is advancing responsibly and strategically.
The Road Ahead for Lantern Pharma
Looking forward, Sharma’s focus remains on scaling RADR and pushing Lantern’s pipeline deeper into clinical trials. By combining artificial intelligence with precision oncology, he is positioning the company as a potential model for small biotech firms seeking to make a large impact.
For patients, this means therapies designed for their specific cancer biology. For investors, it reflects a disciplined, data-backed approach with measurable milestones.
Redefining the Future of Drug Development
Panna Sharma’s career shows how multidisciplinary thinking combining philosophy of science, artificial intelligence, and business strategy can reshape modern biotech leadership.
At Lantern Pharma, he has championed seven powerful moves advancing the RADR platform, prioritizing biomarker-driven studies, targeting underserved patient populations, building subsidiaries like Starlight, adapting trial designs, forging strategic collaborations, and communicating with clarity.
By focusing on efficiency, precision, and adaptability, Sharma is proving that even smaller biotech companies can make an outsized impact in oncology research. His leadership at Lantern Pharma may well become a blueprint for the future of cancer drug development.
